Hope on the horizon – Extending access to GLP-1 Receptor Agonists for T2DM patients with chronic obesity

shutterstock_2369994581 - home page

Unmet needs in the management of T2DM include improving glucose control, avoiding weight gain and protecting your patients heart, brain, kidney, nerves and eyesight

Learning objectives

You will learn:

  • Understand the long-term benefits for your T2DM patients of the GLP-1RAs in terms of achieving better glycaemic control and reducing long-term CV, Renal and Metabolic complications over the duration of their diabetes
  • Encourage patients to adopt life-style changes and improve adherence and commitment to their therapeutic regimens which now offer much greater health benefits over the duration of their diabetes
  • Contribute to better health care by encouraging funders and public sector formularies to make these agents more accessible to South African patients as generic GLP-1RAs become available in the country.
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.

To access this module, please register or login: